IL1RL2

Summary

IL1RL2 (interleukin 1 receptor like 2, HGNC:5999) is a protein-coding gene on chromosome 2q12.1, encoding Interleukin-1 receptor-like 2 (Q9HB29). Receptor for interleukin-36 (IL36A, IL36B and IL36G).

The protein encoded by this gene is a member of the interleukin 1 receptor family. An experiment with transient gene expression demonstrated that this receptor was incapable of binding to interleukin 1 alpha and interleukin 1 beta with high affinity. This gene and four other interleukin 1 receptor family genes, including interleukin 1 receptor, type I (IL1R1), interleukin 1 receptor, type II (IL1R2), interleukin 1 receptor-like 1 (IL1RL1), and interleukin 18 receptor 1 (IL18R1), form a cytokine receptor gene cluster in a region mapped to chromosome 2q12.

Source: NCBI Gene 8808 — RefSeq curated summary.

At a glance

• GWAS associations: 37
• Clinical variants (ClinVar): 107 total
• Druggable target: yes
• MANE Select transcript: NM_003854

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5999
Approved symbol	IL1RL2
Name	interleukin 1 receptor like 2
Location	2q12.1
Locus type	gene with protein product
Status	Approved
Aliases	IL1R-rp2, IL1RRP2, IL-36R
Ensembl gene	ENSG00000115598
Ensembl biotype	protein_coding
OMIM	604512
Entrez	8808

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 8 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000264257, ENST00000421464, ENST00000441515, ENST00000481806, ENST00000908896, ENST00000908897, ENST00000908898, ENST00000908899, ENST00000908900

RefSeq mRNA: 6 — MANE Select: NM_003854 NM_001351446, NM_001351447, NM_001351448, NM_001351449, NM_001351450, NM_003854

CCDS: CCDS2056, CCDS86867

Canonical transcript exons

ENST00000264257 — 12 exons

Exon	Start	End
ENSE00000772430	102191925	102192120
ENSE00000804352	102189076	102189310
ENSE00001359836	102187023	102187086
ENSE00001868228	102239192	102240002
ENSE00003476389	102219881	102220017
ENSE00003479516	102187856	102187925
ENSE00003494047	102232963	102233124
ENSE00003522902	102234897	102235277
ENSE00003575069	102225898	102226041
ENSE00003624034	102218953	102219082
ENSE00003636847	102201556	102201715
ENSE00003678987	102212100	102212174

Expression profiles

Bgee: expression breadth ubiquitous, 153 present calls, max score 88.20.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1433 / max 82.0876, expressed in 40 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
21699	0.1433	40

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.20	gold quality
skin of abdomen	UBERON:0001416	80.43	gold quality
skin of leg	UBERON:0001511	79.67	gold quality
lower esophagus mucosa	UBERON:0035834	79.32	gold quality
esophagus mucosa	UBERON:0002469	77.11	gold quality
zone of skin	UBERON:0000014	76.86	gold quality
right lobe of thyroid gland	UBERON:0001119	71.44	gold quality
right lobe of liver	UBERON:0001114	71.15	gold quality
cartilage tissue	UBERON:0002418	70.77	silver quality
left lobe of thyroid gland	UBERON:0001120	70.62	gold quality
thyroid gland	UBERON:0002046	69.61	gold quality
right uterine tube	UBERON:0001302	69.39	gold quality
minor salivary gland	UBERON:0001830	68.58	gold quality
mucosa of transverse colon	UBERON:0004991	68.46	gold quality
gall bladder	UBERON:0002110	68.20	gold quality
left adrenal gland	UBERON:0001234	68.00	gold quality
left adrenal gland cortex	UBERON:0035825	67.77	gold quality
amniotic fluid	UBERON:0000173	67.38	silver quality
right adrenal gland	UBERON:0001233	67.09	gold quality
islet of Langerhans	UBERON:0000006	67.05	gold quality
buccal mucosa cell	CL:0002336	66.93	gold quality
vagina	UBERON:0000996	66.75	gold quality
right adrenal gland cortex	UBERON:0035827	66.68	gold quality
mouth mucosa	UBERON:0003729	66.42	gold quality
adrenal cortex	UBERON:0001235	65.64	gold quality
metanephros cortex	UBERON:0010533	64.97	gold quality
saliva-secreting gland	UBERON:0001044	64.81	gold quality
prefrontal cortex	UBERON:0000451	64.33	gold quality
rectum	UBERON:0001052	64.30	gold quality
esophagus	UBERON:0001043	64.25	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.56

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

9 targeting IL1RL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-6882-5P	99.35	71.13	1206
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-922	99.02	67.23	1838
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-4689	96.97	65.79	1209
HSA-MIR-6858-5P	96.05	64.59	1020

Literature-anchored findings (GeneRIF, showing 16)

• IL-1alpha and IL-1beta gene polymorphisms do not act as a strong susceptibility factor for MTLE-HS in individuals of Turkish ancestry (PMID:16546408)
• Expression of IL-1Rrp2 by sone dendritic cell subsets may have an important function in the human immune response in vivo via its role in differentiation of inflammatory Th1 lymphocytes. (PMID:22144259)
• These data provide evidence that IL-38 binds to the IL-36R, as does IL-36Ra.[IL-38, IL-36R] (PMID:22315422)
• IL36A-IL36R axis is modulated in patients with primary Sjogren’s syndrome. (PMID:25902739)
• The ubiquitin-binding Tollip protein contributed to IL-36R signaling and increased the accumulation of both subunits of the IL-36R. (PMID:26269592)
• The data identify a novel role for IL-36 signaling in colonic inflammation and indicate that the IL-36R pathway may represent a novel target for therapeutic intervention. (PMID:26813344)
• All human blood lymphocytes express IL-36R. (PMID:27269181)
• single nucleotide polymorphism A471T in the Toll-interleukin 1 receptor domain (TIR) of the IL-1Rrp2 that is present in approximately 2% of the human population, down-regulated IL-36R signaling by a decrease of interaction with IL-1RAcP. (PMID:27307043)
• Endothelial cells, including dermal microvascular cells, express a functionally active IL-36 receptor. (PMID:27673278)
• The IL36 receptor (IL1RL2) is an important mediator molecule in the inflammatory response. (PMID:27853811)
• Serum IL-36 cytokines levels in type 2 diabetes mellitus patients and their association with obesity, insulin resistance, and inflammation. (PMID:33034926)
• Interleukin-1 Receptor-Like 2: One Receptor, Three Agonists, and Many Implications. (PMID:35171706)
• Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis. (PMID:36482185)
• Myeloid cell-derived proteases produce a proinflammatory form of IL-37 that signals via IL-36 receptor engagement. (PMID:36525507)
• In Silico and In Vitro Analysis of IL36RN Alterations Reveals Critical Residues for the Function of the Interleukin-36 Receptor Complex. (PMID:37414245)
• Emerging Role of the IL-36/IL-36R Axis in Multiple Inflammatory Skin Diseases. (PMID:38189700)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Il1rl2	ENSMUSG00000070942
rattus_norvegicus	Il1rl2	ENSRNOG00000014683

Paralogs (10): LAG3 (ENSG00000089692), IL1R2 (ENSG00000115590), IL1R1 (ENSG00000115594), IL1RL1 (ENSG00000115602), IL18R1 (ENSG00000115604), IL18RAP (ENSG00000115607), IL1RAPL1 (ENSG00000169306), SIGIRR (ENSG00000185187), IL1RAPL2 (ENSG00000189108), IL1RAP (ENSG00000196083)

Protein

Protein identifiers

Interleukin-1 receptor-like 2 — Q9HB29 (reviewed: Q9HB29)

Alternative names: IL-36 receptor, Interleukin-1 receptor-related protein 2

All UniProt accessions (2): Q9HB29, C9K0I8

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for interleukin-36 (IL36A, IL36B and IL36G). After binding to interleukin-36 associates with the coreceptor IL1RAP to form the interleukin-36 receptor complex which mediates interleukin-36-dependent activation of NF-kappa-B, MAPK and other pathways. The IL-36 signaling system is thought to be present in epithelial barriers and to take part in local inflammatory response; it is similar to the IL-1 system. Seems to be involved in skin inflammatory response by induction of the IL-23/IL-17/IL-22 pathway.

Subunit / interactions. Interacts with IL1RAP; the association is enhanced by IL36B indicative for an functional signaling complex and inhibited by IL36RN.

Subcellular location. Membrane.

Tissue specificity. Expressed in synovial fibroblasts and articular chondrocytes. Expressed in keratinocytes and monocyte-derived dendritic cells. Expressed in monocytes and myeloid dendritic cells; at protein level.

Domain organisation. The TIR domain mediates NAD(+) hydrolase (NADase) activity. Self-association of TIR domains is required for NADase activity.

Similarity. Belongs to the interleukin-1 receptor family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9HB29-1	1	yes
Q9HB29-2	2

RefSeq proteins (6): NP_001338375, NP_001338376, NP_001338377, NP_001338378, NP_001338379, NP_003845* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000157	TIR_dom	Domain
IPR003599	Ig_sub	Domain
IPR004074	IL-1_rcpt_I/II-typ	Family
IPR004076	IL-1_rcpt_I-typ	Family
IPR007110	Ig-like_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR015621	IL-1_rcpt_fam	Family
IPR035897	Toll_tir_struct_dom_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily

Pfam: PF01582, PF13895

Catalyzed reactions (Rhea), 1 shown:

• NAD(+) + H2O = ADP-D-ribose + nicotinamide + H(+) (RHEA:16301)

UniProt features (51 total): strand 16, glycosylation site 9, domain 4, disulfide bond 3, splice variant 3, sequence variant 3, sequence conflict 3, helix 3, topological domain 2, signal peptide 1, chain 1, transmembrane region 1, turn 1, active site 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9ETH	X-RAY DIFFRACTION	2.3
6U6U	X-RAY DIFFRACTION	2.31
9ETI	X-RAY DIFFRACTION	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HB29-F1	77.84	0.24

Antibody-complex structures (SAbDab): 1 — 6U6U

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 467

Disulfide bonds (3): 42–95, 146–195, 249–316

Glycosylation sites (9): 41, 59, 109, 127, 184, 234, 250, 266, 299

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-9007892	Interleukin-38 signaling
R-HSA-9014826	Interleukin-36 pathway

MSigDB gene sets: 156 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, chr2q12, GOCC_CELL_SURFACE, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, GOBP_CELL_CELL_ADHESION, GOBP_REGULATION_OF_LEUKOCYTE_DIFFERENTIATION, GOBP_REGULATION_OF_HEMOPOIESIS, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_PRODUCTION_OF_MOLECULAR_MEDIATOR_INVOLVED_IN_INFLAMMATORY_RESPONSE

GO Biological Process (11): inflammatory response (GO:0006954), cellular defense response (GO:0006968), signal transduction (GO:0007165), cell surface receptor signaling pathway (GO:0007166), positive regulation of interleukin-6 production (GO:0032755), innate immune response (GO:0045087), positive regulation of T cell differentiation (GO:0045582), regulation of inflammatory response (GO:0050727), immune system process (GO:0002376), cytokine-mediated signaling pathway (GO:0019221), interleukin-1-mediated signaling pathway (GO:0070498)

GO Molecular Function (5): interleukin-1 receptor activity (GO:0004908), interleukin-1, type I, activating receptor activity (GO:0004909), NAD+ nucleosidase activity, cyclic ADP-ribose generating (GO:0061809), hydrolase activity (GO:0016787), signaling receptor activity (GO:0038023)

GO Cellular Component (3): plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Interleukin-1 family signaling	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
defense response	2
cellular anatomical structure	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
signal transduction	1
positive regulation of cytokine production	1
interleukin-6 production	1
regulation of interleukin-6 production	1
immune response	1
defense response to symbiont	1
T cell differentiation	1
regulation of T cell differentiation	1
positive regulation of lymphocyte differentiation	1
positive regulation of T cell activation	1
inflammatory response	1
regulation of defense response	1
regulation of response to external stimulus	1
biological_process	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
cytokine-mediated signaling pathway	1
cellular response to interleukin-1	1
cytokine receptor activity	1
interleukin-1 binding	1
interleukin-1 receptor activity	1
interleukin-1-mediated signaling pathway	1
hydrolase activity, hydrolyzing N-glycosyl compounds	1
catalytic activity	1
molecular transducer activity	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

748 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL1RL2	IL36RN	Q9UBH0	993
IL1RL2	IL1F10	Q8WWZ1	992
IL1RL2	IL1RAP	Q9NPH3	987
IL1RL2	IL36A	Q9UHA7	966
IL1RL2	IL1R1	P14778	963
IL1RL2	IL36B	Q9NZH7	912
IL1RL2	NDUFAB1	O14561	885
IL1RL2	IL1A	P01583	855
IL1RL2	IL1B	P01584	818
IL1RL2	IL36G	Q9NZH8	805
IL1RL2	IL33	O95760	721
IL1RL2	IL18R1	Q13478	671
IL1RL2	IL37	Q9NZH6	645
IL1RL2	CARD14	Q9BXL6	621
IL1RL2	MYD88	P78397	609

IntAct

3 interactions, top by confidence:

A	B	Type	Score
IL1RL2	MYO1F	psi-mi:“MI:0914”(association)	0.350
IL1RL2	DNAJC6	psi-mi:“MI:0914”(association)	0.350

BioGRID (19): IL1RL2 (Affinity Capture-Western), POTEI (Affinity Capture-MS), DNAJC6 (Affinity Capture-MS), MYO1F (Affinity Capture-MS), MICAL1 (Affinity Capture-MS), ACTB (Affinity Capture-MS), GET4 (Affinity Capture-MS), IL1RL2 (Biochemical Activity), IL1RL2 (Biochemical Activity), IL1RL2 (Biochemical Activity), IL1RL2 (Co-localization), IL1RL2 (Affinity Capture-Western), IL1RL2 (Synthetic Lethality), GET4 (Affinity Capture-MS), DNAJC6 (Affinity Capture-MS)

ESM2 similar proteins: A3KPA0, A5A6L6, A5D7C3, O60487, O70255, O88792, P01865, P01903, P01904, P01910, P04224, P04228, P14434, P14439, P14778, P15980, P22646, P23150, P53788, P57087, P59822, P97952, Q00954, Q02955, Q07699, Q17QN4, Q1WIM2, Q28740, Q2WGK2, Q30631, Q3TEW6, Q3V3F6, Q4PPC4, Q5EAB0, Q5R804, Q61730, Q62929, Q63621, Q66KX2, Q68FQ2

Diamond homologs: P13504, P14778, P27930, P43303, Q02955, Q29612, Q62929, Q9ERS7, Q9HB29, P27931, Q9NP60, B2LT62, B2LT65, Q0GC71, Q4V892, Q63621, Q6IA17, Q9JLZ8, Q9V477, A2TF48, B3Y678, B3Y679, B3Y680, B3Y681, B3Y682, B3Y683, B6CJX2, C8BKC7, P22366, P59822, Q599T9, Q61730, Q6Y1S1, Q99836, Q9NPH3

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
IL1F10	“down-regulates activity”	IL1RL2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

107 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	81
Likely benign	9
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2087 predictions. Top by Δscore:

Variant	Effect	Δscore
2:102201675:G:T	donor_gain	1.0000
2:102201716:G:GG	donor_gain	1.0000
2:102219078:GTGGA:G	donor_gain	1.0000
2:102219080:GGA:G	donor_gain	1.0000
2:102219081:GAG:G	donor_gain	1.0000
2:102219083:G:GG	donor_gain	1.0000
2:102219877:ATAG:A	acceptor_loss	1.0000
2:102219878:TA:T	acceptor_loss	1.0000
2:102219879:A:AG	acceptor_gain	1.0000
2:102219879:AG:A	acceptor_loss	1.0000
2:102219880:G:GA	acceptor_gain	1.0000
2:102219880:GA:G	acceptor_gain	1.0000
2:102219880:GAACC:G	acceptor_gain	1.0000
2:102225886:T:A	acceptor_gain	1.0000
2:102225896:A:AG	acceptor_gain	1.0000
2:102225897:G:GG	acceptor_gain	1.0000
2:102226037:AGTAG:A	donor_loss	1.0000
2:102226040:AGG:A	donor_loss	1.0000
2:102226041:GGTA:G	donor_loss	1.0000
2:102226043:T:G	donor_loss	1.0000
2:102233080:GATA:G	donor_gain	1.0000
2:102234893:CCAGC:C	acceptor_loss	1.0000
2:102234894:CA:C	acceptor_loss	1.0000
2:102234895:A:AG	acceptor_gain	1.0000
2:102234895:AGCC:A	acceptor_gain	1.0000
2:102234896:G:GG	acceptor_gain	1.0000
2:102234896:GC:G	acceptor_gain	1.0000
2:102234896:GCC:G	acceptor_gain	1.0000
2:102234896:GCCG:G	acceptor_gain	1.0000
2:102234896:GCCGT:G	acceptor_gain	1.0000

AlphaMissense

3773 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:102219017:G:C	W263C	0.997
2:102219017:G:T	W263C	0.997
2:102219015:T:A	W263R	0.993
2:102219015:T:C	W263R	0.993
2:102219972:T:A	C316S	0.993
2:102219973:G:C	C316S	0.993
2:102192112:T:A	W161R	0.992
2:102192112:T:C	W161R	0.992
2:102218973:T:A	C249S	0.992
2:102218974:G:C	C249S	0.992
2:102192114:G:C	W161C	0.990
2:102192114:G:T	W161C	0.990
2:102232987:T:A	V387D	0.986
2:102218974:G:A	C249Y	0.985
2:102219016:G:C	W263S	0.985
2:102219972:T:C	C316R	0.985
2:102233089:T:C	L421S	0.985
2:102189183:T:A	W56R	0.984
2:102189183:T:C	W56R	0.984
2:102219967:T:C	F314S	0.984
2:102201649:T:A	C195S	0.983
2:102201650:G:C	C195S	0.983
2:102218973:T:C	C249R	0.983
2:102189185:G:C	W56C	0.982
2:102189185:G:T	W56C	0.982
2:102232980:G:C	A385P	0.982
2:102233091:T:C	F422L	0.982
2:102233093:T:A	F422L	0.982
2:102233093:T:G	F422L	0.982
2:102235181:T:C	F528L	0.982

dbSNP variants (sampled 300 via entrez): RS1000126695 (2:102210152 A>G,T), RS1000205348 (2:102218268 G>A), RS1000208957 (2:102185282 C>G,T), RS1000285214 (2:102212036 C>A,T), RS1000432734 (2:102228106 T>C), RS1000471999 (2:102206013 C>T), RS1000484277 (2:102216816 G>A), RS1000538724 (2:102188108 C>A,T), RS1000602362 (2:102194315 A>G), RS1000614484 (2:102200083 G>A), RS1000617356 (2:102233687 A>G), RS1000733529 (2:102233267 A>T), RS1000749109 (2:102194245 C>G), RS1000765036 (2:102233398 C>A), RS1000833494 (2:102187994 GC>G,GCC)

Disease associations

OMIM: gene MIM:604512 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

37 associations (top):

Study	Trait	p-value
GCST000612_30	Celiac disease	1.000000e-15
GCST001725_46	Inflammatory bowel disease	3.000000e-20
GCST002083_12	Self-reported allergy	2.000000e-16
GCST002137_6	Waist circumference	5.000000e-06
GCST002166_3	Serum protein levels (sST2)	4.000000e-16
GCST002166_4	Serum protein levels (sST2)	2.000000e-11
GCST003129_29	Primary biliary cholangitis	5.000000e-09
GCST003987_5	Asthma	5.000000e-31
GCST004131_93	Inflammatory bowel disease	5.000000e-11
GCST004132_63	Crohn’s disease	6.000000e-11
GCST005038_122	Allergic disease (asthma, hay fever or eczema)	4.000000e-26
GCST005212_18	Asthma	4.000000e-21
GCST005213_1	Asthma (childhood onset)	5.000000e-13
GCST006088_43	Familial squamous cell lung carcinoma	1.000000e-06
GCST006585_2809	Blood protein levels	9.000000e-32
GCST006862_21	Asthma	9.000000e-20
GCST007563_2	Allergic disease (asthma, hay fever or eczema)	4.000000e-24
GCST007564_34	Asthma or allergic disease (pleiotropy)	2.000000e-27
GCST007797_10	Asthma onset (childhood vs adult)	7.000000e-27
GCST007797_14	Asthma onset (childhood vs adult)	1.000000e-12
GCST007797_21	Asthma onset (childhood vs adult)	3.000000e-08
GCST007798_17	Asthma	1.000000e-19
GCST007798_18	Asthma	2.000000e-28
GCST007798_19	Asthma	5.000000e-71
GCST007798_20	Asthma	2.000000e-56
GCST007799_39	Asthma (adult onset)	1.000000e-32
GCST007799_40	Asthma (adult onset)	1.000000e-31
GCST007800_19	Asthma (childhood onset)	5.000000e-37
GCST007800_55	Asthma (childhood onset)	9.000000e-59
GCST007993_13	Asthma (adult onset)	4.000000e-12

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0006953	family history of lung cancer
EFO:0004847	age at onset
EFO:1002011	adult onset asthma
EFO:0009958	response to bisphosphonate
EFO:0009960	atypical femoral fracture

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4665591 (PROTEIN COMPLEX)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Immunoglobulin-like family of IL-1 receptors

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
MAB92	Antagonist	10.62	pKd
spesolimab	Binding	10.52	pKd

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases expression	2
Cadmium	decreases expression, increases abundance, affects cotreatment	2
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
bisphenol A	affects cotreatment, increases methylation	1
titanium dioxide	affects expression	1
beta-lapachone	increases expression	1
zinc sulfide	affects cotreatment, decreases expression	1
CGP 52608	increases reaction, affects binding	1
2-palmitoylglycerol	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Diethylhexyl Phthalate	decreases expression	1
Selenium	affects cotreatment, decreases expression	1
Silver	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Fullerenes	affects expression	1

Cellosaurus cell lines

2 cell lines: 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E6U9	Genomeditech HEK-293 H_IL36 Reporter	Transformed cell line	Female
CVCL_E8EH	HEK-Blue IL-36	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.